EUVIMEDEUVIMED entdecken
Fallbericht

Clinical and genomic characterization of an ATRA ‐insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion

Justin K Kirkham, Yen-Chun Liu, Scott G Foy, Jing Ma, Gabriela Gheorghe, Larissa V Furtado, Marcela I Popescu, Jeffery M Klco, Seth E Karol, Patrick R Blackburn

Genes, Chromosomes and Cancer · 2023

DOI: 10.1002/gcc.23180 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2023. Verfasst von Justin K Kirkham und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The promyelocytic leukemia‐retinoic acid receptor‐α ( PML::RARA ) fusion is the hallmark of acute promyelocytic leukemia (APL) and is observed in over 95% of APL cases. RARA and homologous receptors RARB and RARG are occasionally fused to other gene partners, which differentially affect sensitivity to targeted therapies. Most APLs without RARA fusions have rearrangements involving RARG or RARB , both of which frequently show resistance to all‐trans‐retinoic acid (ATRA) and/or multiagent chemotherapy for acute myeloid leukemia (AML). We present a 13‐year‐old male diagnosed with variant APL with a novel FNDC3B::RARB in‐frame fusion that showed no response to ATRA but responded well to conventional AML therapy. While FNDC3B has been identified as a rare RARA translocation partner in ATRA‐sensitive variant APL, it has never been reported as a fusion partner with RARB and it is only the second known fusion partner with RARB in variant APL. We also show that this novel fusion confers an RNA expression signature that is similar to APL, despite clinical resistance to ATRA monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteLeukemia, Myeloid, AcuteMaleHumansAdolescentTranslocation, GeneticTretinoinRetinoic Acid Receptor alphaGenomicsOncogene Proteins, FusionFibronectins

Stichwörter der Autor:innen

FNDC3B::RARBRNA-sequencingacute promyelocytic leukemia (APL)all-trans-retinoic acid (ATRA)exome sequencinggenome sequencing

Substanzen

TretinoinRetinoic Acid Receptor alphaOncogene Proteins, FusionFNDC3B protein, humanFibronectins

Autor:innen und Institutionen

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatric Hematology and Oncology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA.

Zitieren

APA

Kirkham, J. K., Liu, Y. C., Foy, S. G., Ma, J., Gheorghe, G., Furtado, L. V., Popescu, M. I., Klco, J. M., Karol, S. E., & Blackburn, P. R. (2023). Clinical and genomic characterization of an ATRA ‐insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23180

Vancouver

Kirkham JK, Liu YC, Foy SG, Ma J, Gheorghe G, Furtado LV, et al. Clinical and genomic characterization of an ATRA ‐insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion. Genes, Chromosomes and Cancer. 2023. doi:10.1002/gcc.23180

BibTeX
@article{Kirkham2023,
  author = {Kirkham, Justin K and Liu, Yen-Chun and Foy, Scott G and Ma, Jing and Gheorghe, Gabriela and Furtado, Larissa V and Popescu, Marcela I and Klco, Jeffery M and Karol, Seth E and Blackburn, Patrick R},
  title = {Clinical and genomic characterization of an ATRA ‐insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion},
  journal = {Genes, Chromosomes and Cancer},
  year = {2023},
  doi = {10.1002/gcc.23180}
}
Kostenlos starten →